| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/20-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | TRKB; trk-B; GP145-TrkB |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human NTRK2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于NTRK2抗体的3篇参考文献示例(内容为模拟生成，仅供参考)：
1. **文献名称**: "Development of a specific monoclonal antibody for NTRK2 with applications in neurodevelopmental studies"
**作者**: Smith A, et al.
**摘要**: 研究团队开发了一种高特异性的NTRK2单克隆抗体，通过免疫印迹和免疫组化验证其在啮齿类动物和人类脑组织中的表达，并用于探究NTRK2在神经元分化中的作用。
2. **文献名称**: "NTRK2 antibody-based detection of TrkB receptor isoforms in Alzheimer's disease models"
**作者**: Lee JH, et al.
**摘要**: 利用NTRK2抗体分析阿尔茨海默病模型中TrkB受体剪切变体的表达差异，发现特定异构体与突触可塑性损伤相关，为疾病机制提供新线索。
3. **文献名称**: "Targeted therapy screening using NTRK2 antibodies in pediatric gliomas"
**作者**: Garcia R, et al.
**摘要**: 研究通过NTRK2抗体筛选儿童胶质瘤样本，验证其作为融合蛋白检测工具的潜力，支持NTRK抑制剂在特定肿瘤亚型中的精准治疗应用。
(注：以上文献为示例，实际文献需通过PubMed或Google Scholar检索关键词“NTRK2 antibody”或“TrkB antibody”获取。)
The NTRK2 antibody is a critical tool in studying the tropomyosin receptor kinase B (TrkB), encoded by the NTRK2 gene. This receptor, part of the Trk family, binds neurotrophins like brain-derived neurotrophic factor (BDNF) and neurotrophin-4 (NT-4), playing essential roles in neuronal survival, synaptic plasticity, and cognitive functions. Structurally, TrkB consists of an extracellular ligand-binding domain, a transmembrane region, and an intracellular tyrosine kinase domain. NTRK2 antibodies are designed to detect TrkB expression, activation (via phosphorylation), and localization in tissues, enabling research into its physiological and pathological roles.
In neuroscience, NTRK2 antibodies help investigate links between TrkB dysfunction and neurodegenerative diseases (e.g., Alzheimer’s), mood disorders, and epilepsy. In oncology, they aid in identifying TrkB overexpression or fusion proteins resulting from NTRK2 gene rearrangements, which drive tumorigenesis in certain cancers. Such fusions are rare but actionable targets for FDA-approved TRK inhibitors like larotrectinib. Additionally, these antibodies are vital in validating diagnostic assays and preclinical studies for targeted therapies. Challenges include ensuring specificity due to homology among Trk receptors and distinguishing full-length TrkB from truncated isoforms. Overall, NTRK2 antibodies serve as indispensable tools for unraveling TrkB's multifaceted roles and advancing therapeutic strategies in neurology and oncology.
×
